644 related articles for article (PubMed ID: 28785140)
1. Current research and treatment for gastrointestinal stromal tumors.
Lim KT; Tan KY
World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
4. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
5. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
[TBL] [Abstract][Full Text] [Related]
7. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors: what do we know now?
Corless CL
Mod Pathol; 2014 Jan; 27 Suppl 1():S1-16. PubMed ID: 24384849
[TBL] [Abstract][Full Text] [Related]
9. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.
Vallilas C; Sarantis P; Kyriazoglou A; Koustas E; Theocharis S; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419029
[TBL] [Abstract][Full Text] [Related]
11. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
13. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Xu J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumors of the stomach.
Bennett JJ; Rubino MS
Surg Oncol Clin N Am; 2012 Jan; 21(1):21-33. PubMed ID: 22098829
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal Stromal Tumors.
von Mehren M; Joensuu H
J Clin Oncol; 2018 Jan; 36(2):136-143. PubMed ID: 29220298
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
17. Classification of gastrointestinal stromal tumor syndromes.
Gopie P; Mei L; Faber AC; Grossman SR; Smith SC; Boikos SA
Endocr Relat Cancer; 2018 Feb; 25(2):R49-R58. PubMed ID: 29170162
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the molecular heterogeneity of gastrointestinal stromal tumors and related research: A systematic review.
Ding H; Yu X; Yu Y; Lao X; Hang C; Gao K; Jia Y; Yan Z
Oncol Rep; 2020 Mar; 43(3):751-764. PubMed ID: 32020209
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
